Open label extension study of oral triple kinase inhibitor in IPF pts. BIPI 1199.33

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.